Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Lung and Upper Aerodigestive Cancer Research Group

Publications

View All  |  2014-2010  |  2009-2005

  • Hecht SS, Szabo E. Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer. Cancer Prev Res (Phila). 2014 Jan;7(1):1-8.
    [ PubMed Abstract ]
  • Berg AK, Allen Ziegler K, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Mandrekar SJ, Limburg PJ, Reid JM. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. J Clin Pharmacol. 2013 Apr;53(4):403-12.
    [ PubMed Abstract ]
  • Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; SERM steele. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013 May 25;381(9880):1827-34. Epub 2013 Apr 30. Review.
  • Kelly RJ, Thomas A, Rajan A, chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Ann Oncol. 2013 Oct;24(10):2601-6.
    [ PubMed Abstract ]
  • Limburg PJ, Mandrekar SJ, Aubry MC, Allen Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J. Randomized phase II trial of sulindac for lung cancer prevention. Lung Cancer. 2013 Mar;79(3):254-61.
    [ PubMed Abstract ]
  • Lingen M, Szabo E. Validation of LOH profiles for assessing oral cancer risk. Cancer Prev Res (Phila). 2012 Sep;5(9):1075-7.
    [ PubMed Abstract ]
  • Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ. Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis. Cancer Prev Res (Phila). 2013 May;6(5):448-54.
    [ PubMed Abstract ]
  • Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJ. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013 Jul;6(7):646-55.
    [ PubMed Abstract ]
  • Szabo E, Mao J, Lam S, Reid M, Keith R. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed, American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e40S-60S.
    [ PubMed Abstract ]
  • Thomas A, Mena E, Kurdziel K, Venzon D, Khozin S, Berman A, Choyke P, Szabo E, Rajan A, Giaccone G. 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors. Clin Cancer Res. 2013 Mar 15;19(6):1487-93.
    [ PubMed Abstract ]
  • Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, Arai A, Schrump DS, Kwong KF, Rajan A, Giaccone G. Brief report: characterization and management of cardiac involvement of thymic epithelial tumors. J Thorac Oncol. 2013 Feb;8(2):246-9.
    [ PubMed Abstract ]
  • Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M. Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. Clin Lung Cancer. 2013 Jul;14(4):452-6.
    [ PubMed Abstract ]
  • Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet RA, You M. Chemopreventive effect of a mixture of Chinese Herbs (antitumor B) on chemically induced oral carcinogenesis. Mol Carcinog. 2013 Jan;52(1):49-56.
    [ PubMed Abstract ]
  • Wong SJ, Campbell B, Massey B, Lynch DP, Cohen EW, Blair E, Stenson K, Selle R, Shklovskaya J, Jovanovic BD, Skripkauskas S, Dew A, Kulesza P, Parimi B, Bergan RC, Szabo E. A phase I trial of aminolevulinic acid-photodynamic therapy for treatment of oral leukoplakia. Oral Oncol. 2013 Sep;49(9):970-6.
    [ PubMed Abstract ]
  • Mohebati A, Knutson A, Zhou XK, Smith JJ, Brown PH, Dannenberg AJ, Szabo E. A web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokers. Contemp Clin Trials. 2012 Sep;33(5):942-8.
    [ PubMed Abstract ]
  • Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res. 2012 Apr 15;18(8):2344-51.
    [ PubMed Abstract ]
  • Doria-Rose VP and Szabo E. Lung Cancer Screening and Prevention of Lung Cancer. In: Current Multidisciplinary Oncology: Lung Cancer. Edited by K Kernstine and K Reckamp. NY, NY: Demos Medical, 2011, pp 53-72.
  • Kelly RJ, Lopez-Chavez A, Szabo E. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Current Drug Targets. 2010 Dec 15. [Epub ahead of print].
    [ PubMed Abstract ]
  • Giaccone G, Rajan A, Berman A, Kelly R, Szabo E, Lopez-Chavez A, Trepel J, Lee M-J, Cao L, Espinoza-Delgado I, Spittler J, Loehrer P. Belinostat Phase II Study in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol, In Press.
  • Meyskens FL, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res, In Press.
  • Reid JM, Walden C, Qin R, Ziegler KLA, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Mandrekar SJ, Ames MM, Limburg PJ. Single-dose Phase 0 exploratory pharmacokinetic clinical trial comparing five oral formulations of SR13668, an orally active AKT pathway inhibitor. Cancer Prev Res, In Press.
  • Veronesi G, Szabo E, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B. Randomized Phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res. 2011 Jan;4(1):34-42. Epub 2010 Dec 16.
    [ PubMed Abstract ]
  • Demaria S, Pikarsky E, Karin M, Coussens LM, Chen Y-C, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, et al. Cancer and inflammation: promise for biological therapy. J Immunother. 2010 May;33(4):335-51.
    [ PubMed Abstract ]
  • Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, Cooper K, Walker D, McWilliams A, Liu G, Szabo E, Brody J, Massion PP, Lenburg ME, Lam S, Bild AH, Spira A. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med. 2010 Apr 7;2(26):26ra25.
    [ PubMed Abstract ]
  • Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman SM, Szabo E, Bonnanni B. Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. Contemp Clin Trials. 2010 Nov;31(6):612-9. Epub 2010 Aug 16.
    [ PubMed Abstract ]
  • Maley CC, Szabo E, Reid BJ. Somatic Evolution in Neoplastic Progression and Cancer Prevention. In: Advances in Understanding the Basic Pathogenesis and Clinical Management of Pre-invasive Disease. Edited by R. Fitzgerald. NY, NY: Springer, 2010, pp 111-128.
  • Sharon E, Kelly RJ, Szabo E. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol. 2010 May 26;2:12
    [ PubMed Abstract ]
  • Smith, JJ, Dunn, B, Greenwald, P (2010). Dynamics of Cancer Prevention. In CH Yarbro, M Frogge, M Goodman, and S Groenwald (Eds.), Cancer Nursing: Principles and Practices (7th Edition). Sudbury, MA: Jones & Bartlett Publishers.
  • Szabo E. Assessing efficacy in early-phase cancer prevention trials: the case of the Ki-67 proliferation index in lung cancer prevention. Cancer Prev Res 2010 Feb;3(2):128-31. Epub 2010 Jan 26.
    [ PubMed Abstract ]
  • Szabo E. Phase II cancer prevention clinical trials. Semin Oncol. 2010 Aug;37(4):359-66. Review.
    [ PubMed Abstract ]
  • Wang Y, James M, Wen W, Lu Y, Szabo E, Lubet RA, You M. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther. 2010 Nov;9(11):3074-82. Epub 2010 Nov 2.
    [ PubMed Abstract ]

Back to top